{
    "title": "106_hr1039",
    "content": "SECTION 1. CREDIT FOR CLINICAL TESTING RESEARCH EXPENSES ATTRIBUTABLE TO CERTAIN QUALIFIED ACADEMIC INSTITUTIONS INCLUDING TEACHING HOSPITALS. An amendment is made to the Internal Revenue Code of 1986 to include a new section 41A for a credit for medical innovation expenses. The new section 41A of the Internal Revenue Code of 1986 provides a medical innovation credit equal to 20% of qualified medical innovation expenses exceeding the medical innovation base period amount. Qualified expenses include payments to qualified academic institutions for clinical testing research activities. The term 'clinical testing research activities' refers to human clinical testing conducted at a qualified academic institution in the development of a product before its approval or licensing. The term 'product' refers to any drug, biologic, or medical device. A 'qualified academic institution' is defined as an educational institution affiliated with an organization described in section 170(b)(1)(A)(iii). \"A qualified academic institution is defined as an educational institution affiliated with an organization described in section 170(b)(1)(A)(iii), including teaching hospitals and medical research organizations.\" The term 'qualified medical innovation expenses' excludes amounts funded by grants or contracts from another person or governmental entity. A charitable research hospital is designated as a cancer center by the National Cancer Institute. The term 'qualified medical innovation expenses' does not include amounts funded by grants or contracts from another person or governmental entity. The 'medical innovation base period amount' is the average annual qualified medical innovation expenses paid by the taxpayer in the three taxable years before the first taxable year after December 31, 1998. Special rules include no credit for clinical testing research conducted outside the United States. The section limits foreign clinical testing for research activities, applies rules similar to section 41, requires taxpayer election for application, and coordinates with other research expenditure credits. The medical innovation expenses credit under section 41A is not considered for the credit allowable under section 41 or 45C. This section does not apply to expenses paid after a specified date. It is part of the general business credit and includes a transition rule in the tax code. The tax code is amended to include a medical innovation expenses credit under section 41A, with a transition rule preventing carryback of the credit before January 1, 1999. Additionally, a new subsection denies a double benefit for qualified medical innovation expenses. The tax code is amended to include a medical innovation expenses credit under section 41A, with a transition rule preventing carryback of the credit before January 1, 1999. A new subsection denies a double benefit for qualified medical innovation expenses by disallowing a deduction equal to the credit determined under section 41A(a). Additionally, a deduction for the unused portion of the credit is addressed in section 196(c) of the Code. The tax code is amended to include a medical innovation expenses credit under section 41A, with a transition rule preventing carryback of the credit before January 1, 1999. Code is amended by resdesignating paragraphs (5) through (8) as paragraphs (6) through (9), respectively, and inserting a new paragraph for the medical innovation expenses credit. The tax code is amended to include a medical innovation expenses credit under section 41A, effective for taxable years starting after December 31, 1998."
}